Nautilus Biotechnology, Inc. (NAUT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 38.50M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 5.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.50M | (m) | $5.49M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $39.28M | (m) | $6.04M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $41.11M | (m) | $6.84M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $44.36M | (m) | $8.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $47.04M | (m) | $10.19M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $49.08M | (m) | $11.76M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $50.48M | (m) | $12.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $50.12M | (m) | $12.65M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $49.83M | (m) | $12.57M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $49.30M | (m) | $12.39M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $47.25M | (m) | $12.14M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $44.37M | (m) | $11.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $41.95M | (m) | $11.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $38.89M | (m) | $11.13M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $37.67M | (m) | $10.38M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $37.98M | (m) | $10.08M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $36.65M | (m) | $9.46M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $34.17M | (m) | $8.71M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $29.35M | (m) | $7.93M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |